Akeso

9926 · HKEX

Public Market Listing

9926HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Akeso are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(12 total)
12Total Assets
1Approved
6Phase 3 / Filed
5Phase 1–2 / Early
14Diseases
Quick filter:
Showing 12 of 12 assets
Target & Modality
Approved
PD-1Monoclonal antibody
Non-Small Cell Lung CancerHepatocellular CarcinomaNasopharyngeal Carcinoma
Phase 3
PD-1×CTLA-4Multispecific antibody
Non-Small Cell Lung CancerCervical CancerHepatocellular Carcinoma
Phase 3
IL-12/23 p40Monoclonal antibody
Psoriasis
Phase 3
PCSK9Monoclonal antibody
Atherosclerotic Cardiovascular DiseaseMixed Hyperlipidemia
Phase 3
IL-17AMonoclonal antibody
Psoriasis
Phase 3
PD-1 + VEGFAMultispecific antibody
Non-Small Cell Lung CancerBiliary Tract CancerColorectal Cancer
Metastatic Colorectal Cancer
Phase 3
IL-4R-alphaMonoclonal antibody
Atopic Dermatitis
Phase 2
IL-4 receptor alpha / ST2Multispecific antibody
Atopic DermatitisAsthmaChronic Spontaneous UrticariaPrurigo Nodularis
Phase 2
TROP2 / Nectin-4 (dual)Antibody–drug conjugate
Non-Small Cell Lung Cancer
Phase 1/2
PD-1 x LAG-3Multispecific antibody
Non-Small Cell Lung Cancer
Phase 1/2
HER3Antibody–drug conjugate
Non-Small Cell Lung Cancer
Phase 1/2
CD47Monoclonal antibody
Acute Myeloid Leukemia

Upcoming events

(43 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (9)
November 2026 (2)
CadonilimabPhase 3Gastric and Gastroesophageal Junction Adenocarcinoma
Est. primary completion 2026-11 · NCT06341335 · CT.gov ↗
What to watch
CadonilimabPhase 2HCC, Hepatocellular Carcinoma
Est. primary completion 2026-11-30 · NCT06984718 · CT.gov ↗
What to watch
December 2026 (7)
IvonescimabPhase 1/2Solid Tumor, Adult
Est. primary completion 2026-12 · NCT05689853 · CT.gov ↗
What to watch
AK129Phase 1/2Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma, Advanced Solid Tumors
Est. primary completion 2026-12 · NCT06943820 · CT.gov ↗
What to watch
IvonescimabPhase 3Triple-Negative Breast Cancer (TNBC)
Est. primary completion 2026-12 · NCT06767527 · CT.gov ↗
What to watch
AK139Phase 2Asthma
Est. primary completion 2026-12-27 · NCT07436221 · CT.gov ↗
What to watch
Cadonilimab + IvonescimabPhase 1/2Metastatic Pancreatic Ductal Adenocarcinoma
Est. primary completion 2026-12-30 · NCT06646055 · CT.gov ↗
What to watch
Ivonescimab + LigufalimabPhase 2Metastatic Triple-negative Breast Cancer, Locally Advanced Triple-negative Breast Cancer
Est. primary completion 2026-12-30 · NCT05227664 · CT.gov ↗
What to watch
Ivonescimab + LigufalimabPhase 1/2Advanced Malignant Tumors
Est. primary completion 2026-12-31 · NCT05229497 · CT.gov ↗
What to watch
2027 (19)
January 2027 (2)
Ivonescimab + LigufalimabPhase 3Head and Neck Squamous Cell Carcinoma
Est. primary completion 2027-01 · NCT06601335 · CT.gov ↗
What to watch
IvonescimabPhase 3Colorectal Adenocarcinoma
Est. primary completion 2027-01-13 · NCT06951503 · CT.gov ↗
What to watch
February 2027 (1)
IvonescimabPhase 1/2Colorectal Cancer With Hepatic Metastases
Est. primary completion 2027-02-28 · NCT07357220 · CT.gov ↗
What to watch
April 2027 (2)
CadonilimabPhase 1/2Advanced Solid Tumor
Est. primary completion 2027-04 · NCT05142423 · CT.gov ↗
What to watch
AK139Phase 2Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Est. primary completion 2027-04-30 · NCT07755371 · CT.gov ↗
What to watch
May 2027 (4)
IvonescimabPhase 1/2Biliary Tract Cancer
Est. primary completion 2027-05 · NCT06938321 · CT.gov ↗
What to watch
IvonescimabPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2027-05 · NCT06928389 · CT.gov ↗
What to watch
Cadonilimab + IvonescimabPhase 2Hepatocellular Carcinoma (HCC)
Est. primary completion 2027-05-10 · NCT07052253 · CT.gov ↗
What to watch
Ivonescimab + LigufalimabPhase 3Pancreatic Cancer
Est. primary completion 2027-05-14 · NCT06953999 · CT.gov ↗
What to watch
July 2027 (1)
ManfidokimabPhase 3Atopic Dermatitis
Est. primary completion 2027-07-10 · NCT06767540 · CT.gov ↗
What to watch
August 2027 (3)
AK139Phase 2Prurigo Nodularis (PN)
Est. primary completion 2027-08 · NCT07883213 · CT.gov ↗
What to watch
IvonescimabPhase 2Pancreatic Cancer
Est. primary completion 2027-08 · NCT07114315 · CT.gov ↗
What to watch
Ivonescimab + AK146D1Phase 2Advanced Non Small Cell Lung Cancer (NSCLC)
Est. primary completion 2027-08-30 · NCT07669779 · CT.gov ↗
What to watch
September 2027 (1)
Ivonescimab + AK146D1Phase 2Advanced Breast Cancer
Est. primary completion 2027-09-01 · NCT07591090 · CT.gov ↗
What to watch
October 2027 (1)
IvonescimabPhase 2Platinum-sensitive Ovarian Cancer
Est. primary completion 2027-10 · NCT06686030 · CT.gov ↗
What to watch
November 2027 (3)
AK129 + LigufalimabPhase 1/2Classic Hodgkin Lymphoma
Est. primary completion 2027-11 · NCT06642792 · CT.gov ↗
What to watch
AK139Phase 2Moderate-to-Severe Atopic Dermatitis
Est. primary completion 2027-11 · NCT07502222 · CT.gov ↗
What to watch
CadonilimabPhase 3Gastric / Gastroesophageal Junction Adenocarcinoma
Est. primary completion 2027-11-17 · NCT07449780 · CT.gov ↗
What to watch
December 2027 (1)
Cadonilimab + Ivonescimab + LigufalimabPhase 2Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Est. primary completion 2027-12 · NCT07245446 · CT.gov ↗
What to watch
2028 (8)
April 2028 (1)
IvonescimabPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2028-04 · NCT06767514 · CT.gov ↗
What to watch
May 2028 (1)
IvonescimabPhase 3Metastatic Colorectal Cancer (CRC)
Est. primary completion 2028-05-31 · NCT07228832 · CT.gov ↗
What to watch
June 2028 (2)
Ivonescimab + AK138D1Phase 1/2Breast Cancer
Est. primary completion 2028-06-06 · NCT07560124 · CT.gov ↗
What to watch
Ivonescimab + AK138D1Phase 1/2Non-Small Cell Lung Cancer
Est. primary completion 2028-06-18 · NCT07623356 · CT.gov ↗
What to watch
August 2028 (1)
Ivonescimab + AK146D1Phase 2Urothelial Carcinoma (UC)
Est. primary completion 2028-08-24 · NCT07636772 · CT.gov ↗
What to watch
September 2028 (1)
IvonescimabPhase 2Non-Small Cell Lung Cancer
Est. primary completion 2028-09 · NCT07158840 · CT.gov ↗
What to watch
December 2028 (2)
IvonescimabPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2028-12-31 · NCT05899608 · CT.gov ↗
What to watch
IvonescimabPhase 3Small Cell Lung Cancer
Est. primary completion 2028-12-31 · NCT07010263 · CT.gov ↗
What to watch
2029 (4)
January 2029 (1)
AK139Phase 2Chronic Spontaneous Urticaria
Est. primary completion 2029-01-08 · NCT07875426 · CT.gov ↗
What to watch
April 2029 (1)
IvonescimabPhase 2Renal Cell Carcinoma, Clear Cell
Est. primary completion 2029-04-12 · NCT07877194 · CT.gov ↗
What to watch
July 2029 (1)
CadonilimabPhase 3Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Est. primary completion 2029-07 · NCT07023315 · CT.gov ↗
What to watch
August 2029 (1)
CadonilimabPhase 3Gastric / Gastroesophageal Junction Adenocarcinoma
Est. primary completion 2029-08-18 · NCT07700979 · CT.gov ↗
What to watch
2030 (3)
March 2030 (1)
CadonilimabPhase 2Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Est. primary completion 2030-03 · NCT07263919 · CT.gov ↗
What to watch
June 2030 (1)
CadonilimabPhase 3Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer
Est. primary completion 2030-06-15 · NCT07412613 · CT.gov ↗
What to watch
October 2030 (1)
IvonescimabPhase 2/3Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC)
Est. primary completion 2030-10-31 · NCT07815665 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(12)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

16 November 2026ApprovalGumokimabNMPA approves gumokimab in active ankylosing spondylitis
CN, NMPA · Source ↗
14 November 2026FDA action dateIvonescimabIvonescimab PDUFA goal action date (EGFRm NSCLC post-TKI)
US, FDA · FDA · Source ↗
5 November 2026Priority reviewIvonescimabNMPA grants priority review to ivonescimab plus chemotherapy in first-line biliary tract cancer
CN, NMPA · Akeso · Source ↗
25 October 2026Topline resultIvonescimabPhase 3 HARMONi-GI1 met its primary endpoint of overall survival
12 August 2026ApprovalIvonescimabNMPA approves ivonescimab plus chemotherapy in first-line squamous NSCLC
CN, NMPA · Source ↗
June 2026PresentationLigufalimabRandomized Phase 2 AK117-206 at EHA 2026: median EFS 9.1 vs 6.9 months with ligufalimab added
February 2026Filing acceptedManfidokimabChina's NMPA accepts Akeso's NDA for manfidokimab (AK120) in atopic dermatitis
CN, NMPA · Akeso · Source ↗
29 January 2026Filing acceptedIvonescimabFDA accepts Summit's BLA for ivonescimab plus chemotherapy (EGFRm NSCLC post-TKI)
US, FDA · FDA · Source ↗
19 January 2026Filing acceptedGumokimabNMPA accepts the gumokimab supplemental NDA for active ankylosing spondylitis
CN, NMPA · Akeso · Source ↗
25 August 2025Topline resultManfidokimabPhase 3 topline: primary endpoints met
Akeso · Source ↗
25 August 2025Topline resultGumokimabAK111-303 (NCT06378697) Phase 3 in ankylosing spondylitis met its primary endpoint
Akeso Inc. · Source ↗
7 November 2023Topline resultCadonilimabAK104-302 (NCT05008783) Phase 3 met its primary endpoint
Akeso (9926.HK) · Source ↗

Financial reports

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$295M$166M$1.0B$72Mreport ↗